The scientific enterprise is based on norms of openness and free exchange, but with advances in stem cell research and related medical therapies, tension is arising because of fairly new policies and practices controlling data and materials sharing and intellectual property, says a statement released by the influential Hinxton Group.

The statement was developed last fall at the University of Manchester in the United Kingdom and discussed 24 January in an event at AAAS.